SCP Vitalife

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Ivenix, Inc. is a medical technology company based in North Andover, Massachusetts, that specializes in developing advanced intravenous (IV) infusion systems. Founded in 2001 and previously known as Fluidnet Corporation, Ivenix focuses on creating innovative solutions to improve infusion delivery in hospital settings. The company's flagship product is a next-generation infusion management system that employs pneumatic technology to accurately measure and control fluid flow, regardless of factors such as bag height, backpressure, patient movement, and fluid viscosity. This system not only simplifies the infusion process but also integrates with clinical information systems, enabling healthcare providers to manage patient infusion data effectively. By aiming to enhance the safety and efficiency of IV therapies, Ivenix is positioned to make a significant impact in the field of medical devices.

MST Medical Surgery Technologies Ltd. develops innovative image analysis software aimed at enhancing surgical procedures in the healthcare sector. Founded in 2005 by entrepreneurs Ziv Tamir and Moti Sholev, the company is headquartered in Tel Aviv, Israel, with an additional office in Apollo Beach, Florida. MST's flagship product, AutoLap, is a robotic image-guided laparoscope positioning system that utilizes advanced image analysis technology to provide surgeons with real-time control during operations, ensuring an optimal field of view. Additionally, the company offers Surgical Training Analytics (STA), a tool designed to capture and analyze images from actual surgeries performed by trainee surgeons. By leveraging artificial intelligence, machine learning, and data analytics, MST aims to empower and automate the surgical environment, thereby improving outcomes for surgeons, healthcare providers, and patients alike.

Sensible Medical Innovation Ltd. specializes in innovative sensing and monitoring technology aimed at managing chronic medical conditions that significantly impact healthcare costs globally. The company has developed a noninvasive heart imaging system specifically designed to monitor and manage lung fluid in patients with heart failure. This technology enables physicians to obtain accurate and actionable measurements of a patient's clinical status, ultimately enhancing treatment quality and improving patients' quality of life. By providing reliable data, Sensible Medical's solutions aim to reduce readmissions for heart failure patients and support better management of this condition.

Lifeward is a medical device company based in Marlborough, Massachusetts, specializing in innovative solutions for individuals with lower limb disabilities. The company develops, manufactures, and markets advanced walking systems, notably the ReWalk Rehabilitation System and the ReWalk Personal System. The ReWalk Rehabilitation System is designed for use in rehabilitation centers, enabling users to walk, stand, sit, and navigate stairs. In contrast, the ReWalk Personal System is intended for everyday use, allowing individuals to engage in activities at home, work, and various outdoor environments. This system supports standing, sitting, and turning, while also facilitating stair climbing and descending. Lifeward's mission is to enhance the quality of life for those with spinal cord injuries by providing robotic technologies that offer significant functional and health benefits across different settings, including clinical environments and everyday life. The company operates primarily in the United States and Europe, with additional sales in Asia, the Middle East, and South America.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Regentis Biomaterials Ltd. is a tissue repair company specializing in the development and commercialization of biodegradable hydrogels aimed at regenerating damaged cartilage tissue. The company's primary product, GelrinC, is a hydrogel designed for the treatment of articular cartilage lesions and is currently undergoing clinical trials. GelrinC serves a range of orthopedic applications, including microfracture and autologous chondrocyte implantation procedures. The hydrogel platform, Gelrin, combines polyethylene glycol diacrylate and denatured fibrinogen, offering both the stability of synthetic materials and the bio-functionality of natural substances. Founded in 2004, Regentis Biomaterials is headquartered in Or-Akiva, Israel, with an additional office in Princeton, New Jersey. The company is committed to enhancing patient health and quality of life through innovative tissue repair solutions.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

Fluidnet was founded in 2002 by a group of medical device professionals who collectively have over 100+ years of industry experience and product innovations. Based on the seacoast of scenic New Hampshire, Fluidnet is just north of Boston, providing access to a rich medical device community and first-rate research and development skills and facilities.

Avedro, Inc. is a medical device and pharmaceutical company specializing in the treatment of corneal disorders, particularly corneal ectatic conditions and refractive errors. The company has developed the Avedro Corneal Remodeling platform, which includes the KXL and Mosaic systems that utilize ultraviolet A (UVA) light, alongside a range of single-use riboflavin drug formulations. These technologies are primarily aimed at treating progressive keratoconus and corneal ectasia following refractive surgery. Avedro also focuses on advancing the science of Thermo-biomechanics, exemplified by its Keraflex procedure, a non-invasive method for corneal reshaping that preserves the cornea's biomechanical integrity. The company's products are marketed to ophthalmologists, hospitals, and ambulatory surgery centers in the United States and through international distributors. Avedro, originally established as ThermalVision, Inc. in 2002, is headquartered in Waltham, Massachusetts, and operates as a subsidiary of Glaukos Corporation.

novoGI Inc. specializes in developing innovative medical devices for gastrointestinal disease management, focusing on solutions that enhance patient care. The company has pioneered a range of nitinol-based compression anastomosis devices, which are designed to facilitate natural reconnection of the intestine following colorectal resection procedures, such as those related to colon cancer treatment. This technology represents a significant advancement in surgical closure methods, utilizing the body's natural healing processes to ensure effective tissue integration. novoGI's products are backed by clinical evidence and have received FDA clearance and CE marking, allowing their use in various healthcare settings. Founded in 1996 and headquartered in Atlanta, Georgia, novoGI also has facilities in Paris, France, and Netanya, Israel, reflecting its global presence in the medical device industry.

Garnet BioTherapeutics is a clinical stage, venture-backed cell therapy company focused on dermal-based regenerative therapy.

Sightline Technologies Ltd. provides medical products and services. The Company designs, develops, and markets a colonoscope with a disposable tube and sheath, which is used for diagnosing and treating abnormalities in the large intestine. Sightline Technologies primarily operates in Israel.

Beta-O2 Technologies Ltd. is a biomedical company based in Rosh HaAyin, Israel, established in 2004. The company specializes in the development of innovative implantable bioreactors, particularly the ßAir Bio-artificial Pancreas, aimed at treating type 1 diabetes (T1D). This device addresses significant challenges associated with islet transplantation, such as the need for lifelong immunosuppressive therapy and the deterioration of islet functionality due to inadequate oxygen supply. The ßAir device is designed for minimally invasive implantation and aims to provide patients with essential pancreatic hormones in the correct ratio, effectively reducing reliance on insulin injections and minimizing the risk of hypoglycemic episodes. Additionally, the bioreactor offers robust protection from the host immune system, thus eliminating the need for immunosuppressive drugs and preventing potential fatal immune reactions to transplanted cells. Beta-O2 Technologies is also working on the ßAir Bio-artificial Adrenal for treating adrenal insufficiency and stress-related disorders.

GeneGrafts Ltd., also known as GreenGrafts Ltd., is a biotechnology company based in Haifa, Israel, specializing in the development of therapeutic products for treating cardiac arrhythmias, Parkinson's disease, and epilepsy. Founded in November 2003, the company focuses on a proprietary technology that modulates excitable tissues through cell therapy. By utilizing grafts isolated from the patient's own body, GeneGrafts aims to create a novel approach to treatment. These grafted cells are designed to integrate functionally and structurally with the target organ, allowing for the modulation of electrical properties based on the expression of specific ion channels. This innovative technology platform holds promise for addressing various neurological disorders and cardiac conditions, providing new avenues for therapeutic intervention.

Can-Fite BioPharma is an Israeli biopharmaceutical company engaged in the discovery and clinical development of therapeutics for cancer and inflammatory diseases. The company specializes in developing orally bioavailable small molecule drugs that target the A3 adenosine receptor (A3AR). Can-Fite's lead drug candidate, Piclidenoson, is currently in a Phase III trial aimed at treating psoriasis. Additionally, Namodenoson, another key product, is advancing into a Phase III trial for hepatocellular carcinoma, the most prevalent form of liver cancer, and is also undergoing a Phase IIb trial for non-alcoholic steatohepatitis. With a robust pipeline of proprietary compounds in advanced clinical stages, Can-Fite is focused on addressing significant unmet medical needs in autoimmune-inflammatory conditions and cancer.